1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Issue 5 (29th February 2020) Authors: Goldman‐Mazur, Sarah; Jurczyszyn, Artur; Castillo, Jorge J.; Waszczuk‐Gajda, Anna; Grząśko, Norbert; Radocha, Jakub; Bittrich, Max; Kortüm, K. Martin; Gozzetti, Alessandro; Usnarska‐Zubkiewicz, Lidia; Davila Valls, Julio; Jayabalan, David S.; Niesvizky, Ruben; Kelman, Julia; Coriu, Daniel; Rosiño... Journal: American journal of hematology Issue: Volume 95:Issue 5(2020:May) Page Start: 503 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight. Issue 3 (May 2021) Authors: Wang, Bo; Rajeeve, Sridevi; Madduri, Deepu Journal: Cancer journal Issue: Volume 27:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021) Authors: Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred... Journal: Lancet Issue: Volume 398:Issue 10297(2021) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022) Authors: Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John... Journal: Lancet Issue: Volume 9:Issue 12(2022) Page Start: e897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. (15th June 2022) Authors: Restrepo, Paula; Bhalla, Sherry; Ghodke-Puranik, Yogita; Aleman, Adolfo; Leshchenko, Violetta; Melnekoff, David T.; Agte, Sarita; Jiang, Joy; Madduri, Deepu; Richter, Joshua; Richard, Shambavi; Chari, Ajai; Cho, Hearn Jay; Jagannath, Sundar; Walker, Christopher J.; Landesman, Yosef; Laganà, Aless... Journal: JCO precision oncology Issue: Volume 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Issue 9 (1st September 2020) Authors: Sanchez, Larysa; Barley, Kevin; Richter, Joshua; Franz, Joseph; Cho, Hearn Jay; Jagannath, Sundar; Madduri, Deepu; Parekh, Samir; Richard, Shambavi; Chari, Ajai Journal: Expert review of hematology Issue: Volume 13:Issue 9(2020) Page Start: 943 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Issue 1 (2nd January 2021) Authors: Richard, Shambavi; Jagannath, Sundar; Cho, Hearn Jay; Parekh, Samir; Madduri, Deepu; Richter, Joshua; Chari, Ajai Journal: Expert review of hematology Issue: Volume 14:Issue 1(2021) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2. Issue 2 (22nd December 2019) Authors: Barley, Kevin; Sanchez, Larysa; Cho, Hearn J.; Parekh, Samir; Madduri, Deepu; Richter, Joshua; Isola, Luis; Goldstein, Talia; Dhadwal, Amishi; Zarychta, Katarzyna; Sanchez, Gillian Morgan; Catamero, Donna; Verina, Daniel; Florendo, Erika; Yum, Moon‐hee; La, Lisa; Gullie, Jude; Chan, Elaine; Jagan... Journal: American journal of hematology Issue: Volume 95:Issue 2(2020:Feb.) Page Start: E51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Selinexor in relapsed/refractory multiple myeloma. (June 2020) Authors: Richter, Joshua; Madduri, Deepu; Richard, Shambavi; Chari, Ajai Journal: Therapeutic advances in hematology Issue: Volume 11(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. (January 2021) Authors: Sanchez, Larysa; Richter, Joshua; Cho, Hearn Jay; Jagannath, Sundar; Madduri, Deepu; Parekh, Samir; Richard, Shambavi; Tam, Lowena; Verina, Daniel; Chari, Ajai Journal: Therapeutic advances in hematology Issue: Volume 12(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗